Sandeep Jauhar, MD
Advanced Heart Failure and Transplant Cardiology · New Hyde Park, NYNPI 1588734933
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,400 of the $33,121 with a category attached, or 88.8%. Scpharmaceuticals Inc. accounts for 95.9% of it on its own, with 8 other manufacturers making up the rest.
Across 52 payments — averaging $636.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scpharmaceuticals Inc.$32K
- Abbott$609
- Medtronic$235
- Endotronix, Inc.$128
- Johnson & Johnson$125
- E.r. Squibb & Sons, L.L.C.$119
- plus $156 from 3 others
What the payments were for
- Speaking & faculty fees$29,40089%
- Travel & lodging$1,1964%
- Food & beverage$2,5038%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Scpharmaceuticals Inc. | 36 | $31,748 |
| Abbott | 6 | $609 |
| Medtronic(2 entities) | 4 | $235 |
| Endotronix, Inc. | 1 | $128 |
| Johnson & Johnson | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Impulse Dynamics (USA) Inc. | 1 | $117 |
| Merck | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,121 in reported general payments places this provider in the 80th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 23 | $25,534 |
| EliquisApixaban | 12 | $9,357 |
| Metoprolol Succinate | 29 | $459 |
| Torsemide | 16 | $174 |
| Furosemide | 31 | $169 |
| Carvedilol | 15 | $124 |
| Atorvastatin Calcium | 20 | $108 |
| Spironolactone | 11 | $74 |
| Valsartan | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in New Hyde Park
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Norbert MoskovitsBrooklyn$159K
- Stephen PanValhalla$159K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.